Geneva, March 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119570) titled 'A single-arm, multicenter, phase II study of sacituzumab tirumotecan combined with tagitanlimab for the treatment of advanced non-small cell lung cancer that has progressed after previous platinum-based chemotherapy and PD-1/PD-L1 inhibitor therapy' on Feb. 28.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: West China Hospital of Sichuan University
Condition:
Advanced non-small cell lung cancer
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-03-02
Target Sample Size: Experimental group:42;
Countries of Recruitment:
China
To know more, visit ht...